<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03310398</url>
  </required_header>
  <id_info>
    <org_study_id>130554</org_study_id>
    <nct_id>NCT03310398</nct_id>
  </id_info>
  <brief_title>Negative-Positive Valence Domains in Anxiety and Depression</brief_title>
  <acronym>RDoC</acronym>
  <official_title>Latent Constructs: Negative-Positive Valence Domains in Anxiety and Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Anxiety and depression are highly prevalent and disabling conditions that frequently&#xD;
      co-occur, and are costly to the individual and society. Despite important advances in our&#xD;
      understanding of these disorders, there is a significant unmet need to identify reliable and&#xD;
      clinically useful tests that can predict prognosis, inform treatment choice for a given&#xD;
      individual, and improve treatment outcomes. The aim of this project is to fill this critical&#xD;
      gap by validating a battery of measures including brain imaging, psychophysiology, behavior,&#xD;
      and self-report that will reliably assess positive and negative affect, or valence, system&#xD;
      functioning in a broad sample of individuals screened for anxiety and depression as part of&#xD;
      their routine primary care visits.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants presenting to the UCSD and UCLA primary care clinics will be screened as part of&#xD;
      their routine visit using the Patient Health Questionnaire (PHQ-9) and Generalized Anxiety&#xD;
      Disorder 7 (GAD-7). Participants who call in will be asked to provide verbal informed consent&#xD;
      for phone screening and the IRB approved Screening Questionnaire and the Overall Anxiety&#xD;
      Severity and Impairment Scale (OASIS) will be administered.&#xD;
&#xD;
      Participants who remain eligible after the phone screening will be asked to return for a&#xD;
      Clinical Interview, Behavioral Session, Biomarker blood draw, (and optional genetics), and&#xD;
      Neuroimaging Session.&#xD;
&#xD;
      All participants will be contacted approximately 3-months later and invited to complete the&#xD;
      same battery of self-report measures completed during the baseline session (described below).&#xD;
      The self-report measures will be administered through a secure on-line survey database. This&#xD;
      data will allow investigators to (1) confirm that participants continue to meet initial&#xD;
      eligibility criteria and are therefore eligible for the full re-test battery and (2) use&#xD;
      baseline measures of positive and negative valence domains to predict changes in symptoms and&#xD;
      functioning.&#xD;
&#xD;
      A subset of 50 participants (n=25 from each UCSD and UCLA) will be randomly selected to&#xD;
      return approximately three months later to complete the same battery of assessments in the&#xD;
      Behavioral and Neuroimaging Sessions to establish test-retest reliability of the latent&#xD;
      constructs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2013</start_date>
  <completion_date type="Actual">June 30, 2017</completion_date>
  <primary_completion_date type="Actual">April 30, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Relationship of latent constructs of positive and negative valence domains and neural indices of reward sensitivity and fear conditioning in treatment seeking depressed and anxious individuals.</measure>
    <time_frame>4 years</time_frame>
    <description>Measure of BOLD % signal difference in brain regions of interest during reward or loss trials for anticipation and outcome phases in a reward paradigm, and conditioning trials in a fear conditioning paradigm.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">248</enrollment>
  <condition>Anxiety</condition>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Anxiety</arm_group_label>
    <description>elevated anxiety (as indicated by a GAD-7 score of 8 or higher)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Depression</arm_group_label>
    <description>elevated anxiety (as indicated by a GAD-7 score of 8 or higher)</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>NeuroImaging</intervention_name>
    <description>standard anatomical and functional imaging</description>
    <arm_group_label>Anxiety</arm_group_label>
    <arm_group_label>Depression</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Psychophysiological</intervention_name>
    <description>Hear rate, Vagal Tone, Skin Conductance, and Startle Reflex Electromyogram</description>
    <arm_group_label>Anxiety</arm_group_label>
    <arm_group_label>Depression</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood biomarkers: Investigators will assess blood biomarkers including norepinephrine,&#xD;
      dopamine, epinephrine, creatinine, soluble cellular adhesion molecules (sICAM, sVCAM), IFN+&#xD;
      (IFN-gamma, IL-6, and TNF-alpha assayed together), and brain-derived neurotrophic factor&#xD;
      (BDNF).&#xD;
&#xD;
      Genetics: Furthermore, as noted later in this section of the application, investigators have&#xD;
      identified abnormalities in functioning of key structures (e.g., amygdala and insula) within&#xD;
      the brain's anxiety circuitry in anxiety-prone subjects and there is evidence that certain&#xD;
      genes (e.g., SLC6A4) influence the extent of activation in these regions. The focus of this&#xD;
      project is to determine to what extent variation in CRF system genes (i.e., CRF, CRF-R1,&#xD;
      CRF-R2, UCN, UCN2, UCN3) is associated with anxiety disorders.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Investigators opted to identify individuals with anxiety or depression in a primary care&#xD;
        setting, which investigators have used successfully to recruit a significant number of&#xD;
        subjects, to maximize generalizability and external validity.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        1. Positive for anxiety and/or depressive symptoms.&#xD;
&#xD;
          2. Score on the PHQ-9 and OASIS.&#xD;
&#xD;
          3. Between the ages of 18-55, inclusive.&#xD;
&#xD;
          4. Have signed informed consent document(s) indicating that participant understands the&#xD;
             purpose of and procedures required for the study and willing to participate in the&#xD;
             study.&#xD;
&#xD;
          5. Have sufficient proficiency in English language to understand and complete interviews,&#xD;
             questionnaires, and all other study procedures.&#xD;
&#xD;
          6. Have telephone or easy access to telephone.&#xD;
&#xD;
          7. History of brain injury with evidence of neurological deficits, neurological&#xD;
             disorders, or severe or unstable medical conditions that might be compromised by&#xD;
             participation in the study (to be determined by primary care provider).&#xD;
&#xD;
          8. Current and regular use of a medication that could affect brain functioning.&#xD;
&#xD;
          9. Must not have MRI contraindications such as: cardiac pacemaker, metal fragments in&#xD;
             eyes/skin/body (shrapnel), aortic/aneurysm clips, prosthesis, by-pass surgery/coronary&#xD;
             artery clips, hearing aid, heart valve replacement, shunt (ventricular or spinal),&#xD;
             electrodes, metal plates/pins/screws/wires, or neuro/bio-stimulators (TENS unit),&#xD;
             persons who have ever been a metal worker/welder, history of eye surgery/eyes washed&#xD;
             out because of metal, inability to lie still on one's back for 60 minutes; prior&#xD;
             neurosurgery; tattoos with metal dyes, unwillingness to remove body piercings, and&#xD;
             pregnancy.&#xD;
&#xD;
         10. Intact or correctable vision and hearing.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin P Paulus, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UC San Diego</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Murray B Stein, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>UC San Diego</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSD Psychiatry Clinical Research</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093-0855</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Insel T, Cuthbert B, Garvey M, Heinssen R, Pine DS, Quinn K, Sanislow C, Wang P. Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry. 2010 Jul;167(7):748-51. doi: 10.1176/appi.ajp.2010.09091379.</citation>
    <PMID>20595427</PMID>
  </reference>
  <reference>
    <citation>Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, Rush AJ, Walters EE, Wang PS; National Comorbidity Survey Replication. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003 Jun 18;289(23):3095-105.</citation>
    <PMID>12813115</PMID>
  </reference>
  <reference>
    <citation>Roy-Byrne P, Craske MG, Sullivan G, Rose RD, Edlund MJ, Lang AJ, Bystritsky A, Welch SS, Chavira DA, Golinelli D, Campbell-Sills L, Sherbourne CD, Stein MB. Delivery of evidence-based treatment for multiple anxiety disorders in primary care: a randomized controlled trial. JAMA. 2010 May 19;303(19):1921-8. doi: 10.1001/jama.2010.608.</citation>
    <PMID>20483968</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>October 23, 2015</study_first_submitted>
  <study_first_submitted_qc>October 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 16, 2017</study_first_posted>
  <last_update_submitted>October 9, 2017</last_update_submitted>
  <last_update_submitted_qc>October 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Martin Paulus</investigator_full_name>
    <investigator_title>Adjunct Professor of Psychiatry</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 18, 2012</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/98/NCT03310398/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

